Pipeline

Sorrento’s R&D is focused on driving innovation in COVID-19, cancer treatment, full pain control and autoimmune diseases

Key Programs Indication Preclinical Phase I Phase II Phase III/Pivotal FDA Approval
COVID-19 Programs  

COVISTIX™ (diagnostic) Rapid Antigen Test

*

Emergency Use Authorization (EUA) in Mexico (COFEPRIS), Brazil (ANVISA), and CE Marked in Europe

COVIMARK™ (diagnostic) Rapid Antigen Test

*

Application submitted in the US and Canada for Emergency Use Authorization (EUA)

VIREX (diagnostic) At Home Diagnostic

60.2%*

EUA Enabling Studies in Q3 2022

COVISHIELD™ (treatment) Neutralizing Antibody (IV) in Outpatients and Inpatients

20%*

FUJOVEE™ (Abivertinib) Severe COVID-19 in ICU Patients

82%*

Pivotal Trial Pending FDA Clearance

OQORY™ (COVI-MSC) ARDS due to COVID-19 in ICU Patients

82%*

Pivotal Trial in Brazil

Mpro Inhibitor (oral pill) Anti-viral

40%*

Omicron mRNA Vaccine Vaccine

20%*

Key Programs Indication Preclinical Phase I Phase II Phase III/Pivotal FDA Approval
Immunotherapy  

FUJOVEE™ (Abivertinib) NSCLC

82%*

FUJOVEE™ (Abivertinib) B Cell Lymphomas

60.2%*

FUJOVEE™ (Abivertinib) Prostate

20%*

FUJOVEE™ (Abivertinib) Lupus

20%*

FUJOVEE™ (Abivertinib) MS

20%*

FUJOVEE™ (Abivertinib) GvHD

20%*

PD-L1 (Socazolimab)* SCLC

82%*

*In Partnership with Lee’s Pharm in China

PD-L1 (STI-3031)** Cervical Cancer

82%*

**In US and in partnership with ImmuneOncia in Korea

CD47 Solid Tumors

40%*

CD38 DAR-T Multiple Myeloma

40%*

CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, and esophageal

40%*

Seprehvec™ oncolytic virus Solid Tumors; CNS Tumors

40%*

BCMA ADC Liquid Tumors

20%*

Bevacizumab-ADNAB™ Endometrial Cancer

40%*

In partnership with Mayo Clinic

Bevacizumab-ADNAB™ Ovarian Cancer

40%*

In partnership with Mayo Clinic

Rituximab-ADNAB™ B-cell Lymphomas

40%*

In partnership with Mayo Clinic

Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL), Melanoma

40%*

Key Programs Indication Preclinical Phase I Phase II Phase III/Pivotal FDA Approval
Pain  

ZTlido® 1.8%
Postherpetic Neuralgia - PHN

99.8%*

Gloperba®
Treatment of Gout (Oral)

99.8%*

SEMDEXA (SP-102) Lumbar Radicular/Sciatica Pain

82%*

SP-103 (Lidocaine Topical System 5.4%) Acute Back Pain

60.2%*

SP-104 (Delayed Burst Low Dose Naltrexone) Fibromyalgia

20%*

RTX (resiniferatoxin)
Epidural injection
Intractable Pain in Advanced Cancer

60.3%*

Orphan designation

RTX (resiniferatoxin)
Intra-articular route
Moderate to Severe Knee OA Pain

60.2%*

Key Programs Indication Preclinical Phase I Phase II Phase III/Pivotal FDA Approval
Lymphatic Drug Delivery  

Sofusa® anti-TNF Autoimmune (RA)

40%*

Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL), Melanoma

40%*

Sofusa® anti-CTLA-4 Melanoma

40%*

In partnership with Mayo Clinic
COVID-19 Programs
Key Programs (Indication) Phase
COVISTIX™ (diagnostic) FDA EUA
COVIMARK™ (diagnostic) FDA EUA
VIREX (diagnostic) PH III
COVISHIELD™ (treatment) PH I
FUJOVEE™ (Abivertinib) Ph III
OQORY™ (COVI-MSC) Ph III
Mpro Inhibitor (oral pill) Ph II
Omicron mRNA Vaccine Preclinical
Immunotherapy
Key Programs (Indication) Phase
FUJOVEE™ (Abivertinib) Ph III
FUJOVEE™ (Abivertinib) Ph II
FUJOVEE™ (Abivertinib) Preclinical
FUJOVEE™ (Abivertinib) Preclinical
FUJOVEE™ (Abivertinib) Preclinical
FUJOVEE™ (Abivertinib) Preclinical
PD-L1 (Socazolimab)* Ph III
PD-L1 (STI-3031)** Ph III
CD47 (Solid Tumors) Ph I
CD38 DAR-T (Multiple Myeloma) Ph I
CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, and esophageal) Ph I
Seprehvec™ oncolytic virus (Solid Tumors; CNS Tumors) PH I
BCMA ADC (Liquid Tumors) Preclinical
Bevacizumab-ADNAB™ (Endometrial Cancer) Ph I
Bevacizumab-ADNAB™ (Ovarian Cancer) Ph I
Rituximab-ADNAB™ (B-cell Lymphomas) Ph I
Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I
Pain
Key Programs (Indication) Phase
ZTlido® 1.8% (Postherpetic Neuralgia - PHN) FDA Approval
Gloperba® 1.8% Treatment of Gout (Oral) FDA Approval
SEMDEXA (SP-102) Ph III
SP-103 (Lidocaine Topical System 5.4%) Ph II
SP-104 (Delayed Burst Low Dose Naltrexone) Preclinical
RTX (resiniferatoxin) Epidural injection Ph II
RTX (resiniferatoxin) Intra-articular route Ph II
Lymphatic Delivery
Key Programs (Indication) Phase II
Sofusa® anti-TNF (Autoimmune RA) Ph I
Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I
Sofusa® anti-CTLA-4 (Melanoma) Ph I